# A Study of PLB-002 in Advanced Solid Tumors

> **NCT07304128** · PHASE1 · RECRUITING · sponsor: **Primelink BioTherapeitics(ShenZhen) Limited** · enrollment: 100 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** PLB-002

## Key facts

- **NCT ID:** NCT07304128
- **Lead sponsor:** Primelink BioTherapeitics(ShenZhen) Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-06
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07304128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07304128, "A Study of PLB-002 in Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT07304128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*